Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients
•A popPK model of posaconazole tablets in allogeneic SCT adult recipients is presented.•Gender and serum proteins showed a significant impact on posaconazole elimination.•A nomogram based on PKPD criteria for MIPD of posaconazole has been developed. Posaconazole is an antifungal agent extensively us...
Saved in:
| Published in | European journal of pharmaceutical sciences Vol. 168; p. 106049 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.01.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0928-0987 1879-0720 1879-0720 |
| DOI | 10.1016/j.ejps.2021.106049 |
Cover
| Abstract | •A popPK model of posaconazole tablets in allogeneic SCT adult recipients is presented.•Gender and serum proteins showed a significant impact on posaconazole elimination.•A nomogram based on PKPD criteria for MIPD of posaconazole has been developed.
Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical response. The aim of this study was to develop a population pharmacokinetic (popPK) model of a posaconazole tablet formulation in allogeneic SCT adult recipients for supporting model-informed precision dosing (MIPD).
Prospective observational study performed in adult allogeneic SCT recipients receiving posaconazole as prophylaxis for IFIs and followed up by a therapeutic drug monitoring (TDM) program. Posaconazole plasma concentrations were quantified using an ultra-high-performance liquid chromatography (UPLC) with UV detector. A popPK model was developed using NONMEM v.7.4.0. Deterministic and stochastic simulations were carried out with the final model to evaluate the differences across physiological variables with impact on drug exposure.
A one-compartment model with sequential absorption (zero and first order) and first order elimination described adequately 55 posaconazole concentrations from 36 patients. Higher doses of posaconazole were found to be required by males and patients with lower values of total serum proteins. A nomogram to estimate the posaconazole daily dose based on pharmacokinetic/pharmacodynamic (PKPD) criterion for males and females for different values of total proteins was developed.
Gender and total serum proteins have been identified as covariates influencing posaconazole CL/F in adult allogeneic SCT recipients receiving the delay-released tablet formulation. Additional studies are required to better characterize the absorption of posaconazole and implications on dosage recommendations together with potential safety concerns.
[Display omitted] |
|---|---|
| AbstractList | Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical response. The aim of this study was to develop a population pharmacokinetic (popPK) model of a posaconazole tablet formulation in allogeneic SCT adult recipients for supporting model-informed precision dosing (MIPD).
Prospective observational study performed in adult allogeneic SCT recipients receiving posaconazole as prophylaxis for IFIs and followed up by a therapeutic drug monitoring (TDM) program. Posaconazole plasma concentrations were quantified using an ultra-high-performance liquid chromatography (UPLC) with UV detector. A popPK model was developed using NONMEM v.7.4.0. Deterministic and stochastic simulations were carried out with the final model to evaluate the differences across physiological variables with impact on drug exposure.
A one-compartment model with sequential absorption (zero and first order) and first order elimination described adequately 55 posaconazole concentrations from 36 patients. Higher doses of posaconazole were found to be required by males and patients with lower values of total serum proteins. A nomogram to estimate the posaconazole daily dose based on pharmacokinetic/pharmacodynamic (PKPD) criterion for males and females for different values of total proteins was developed.
Gender and total serum proteins have been identified as covariates influencing posaconazole CL/F in adult allogeneic SCT recipients receiving the delay-released tablet formulation. Additional studies are required to better characterize the absorption of posaconazole and implications on dosage recommendations together with potential safety concerns. •A popPK model of posaconazole tablets in allogeneic SCT adult recipients is presented.•Gender and serum proteins showed a significant impact on posaconazole elimination.•A nomogram based on PKPD criteria for MIPD of posaconazole has been developed. Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical response. The aim of this study was to develop a population pharmacokinetic (popPK) model of a posaconazole tablet formulation in allogeneic SCT adult recipients for supporting model-informed precision dosing (MIPD). Prospective observational study performed in adult allogeneic SCT recipients receiving posaconazole as prophylaxis for IFIs and followed up by a therapeutic drug monitoring (TDM) program. Posaconazole plasma concentrations were quantified using an ultra-high-performance liquid chromatography (UPLC) with UV detector. A popPK model was developed using NONMEM v.7.4.0. Deterministic and stochastic simulations were carried out with the final model to evaluate the differences across physiological variables with impact on drug exposure. A one-compartment model with sequential absorption (zero and first order) and first order elimination described adequately 55 posaconazole concentrations from 36 patients. Higher doses of posaconazole were found to be required by males and patients with lower values of total serum proteins. A nomogram to estimate the posaconazole daily dose based on pharmacokinetic/pharmacodynamic (PKPD) criterion for males and females for different values of total proteins was developed. Gender and total serum proteins have been identified as covariates influencing posaconazole CL/F in adult allogeneic SCT recipients receiving the delay-released tablet formulation. Additional studies are required to better characterize the absorption of posaconazole and implications on dosage recommendations together with potential safety concerns. [Display omitted] Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical response. The aim of this study was to develop a population pharmacokinetic (popPK) model of a posaconazole tablet formulation in allogeneic SCT adult recipients for supporting model-informed precision dosing (MIPD).BACKGROUNDPosaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical response. The aim of this study was to develop a population pharmacokinetic (popPK) model of a posaconazole tablet formulation in allogeneic SCT adult recipients for supporting model-informed precision dosing (MIPD).Prospective observational study performed in adult allogeneic SCT recipients receiving posaconazole as prophylaxis for IFIs and followed up by a therapeutic drug monitoring (TDM) program. Posaconazole plasma concentrations were quantified using an ultra-high-performance liquid chromatography (UPLC) with UV detector. A popPK model was developed using NONMEM v.7.4.0. Deterministic and stochastic simulations were carried out with the final model to evaluate the differences across physiological variables with impact on drug exposure.MATERIALS AND METHODProspective observational study performed in adult allogeneic SCT recipients receiving posaconazole as prophylaxis for IFIs and followed up by a therapeutic drug monitoring (TDM) program. Posaconazole plasma concentrations were quantified using an ultra-high-performance liquid chromatography (UPLC) with UV detector. A popPK model was developed using NONMEM v.7.4.0. Deterministic and stochastic simulations were carried out with the final model to evaluate the differences across physiological variables with impact on drug exposure.A one-compartment model with sequential absorption (zero and first order) and first order elimination described adequately 55 posaconazole concentrations from 36 patients. Higher doses of posaconazole were found to be required by males and patients with lower values of total serum proteins. A nomogram to estimate the posaconazole daily dose based on pharmacokinetic/pharmacodynamic (PKPD) criterion for males and females for different values of total proteins was developed.RESULTSA one-compartment model with sequential absorption (zero and first order) and first order elimination described adequately 55 posaconazole concentrations from 36 patients. Higher doses of posaconazole were found to be required by males and patients with lower values of total serum proteins. A nomogram to estimate the posaconazole daily dose based on pharmacokinetic/pharmacodynamic (PKPD) criterion for males and females for different values of total proteins was developed.Gender and total serum proteins have been identified as covariates influencing posaconazole CL/F in adult allogeneic SCT recipients receiving the delay-released tablet formulation. Additional studies are required to better characterize the absorption of posaconazole and implications on dosage recommendations together with potential safety concerns.CONCLUSIONSGender and total serum proteins have been identified as covariates influencing posaconazole CL/F in adult allogeneic SCT recipients receiving the delay-released tablet formulation. Additional studies are required to better characterize the absorption of posaconazole and implications on dosage recommendations together with potential safety concerns. |
| ArticleNumber | 106049 |
| Author | Rebollo, Noemí Vázquez-López, Lourdes Pérez-Blanco, Jonás Samuel Peña-Lorenzo, Diego Otero, María José Sánchez-Hernández, José Germán Zarzuelo-Castañeda, Aránzazu |
| Author_xml | – sequence: 1 givenname: Diego surname: Peña-Lorenzo fullname: Peña-Lorenzo, Diego organization: Pharmacy Service, University Hospital of Salamanca, Spain – sequence: 2 givenname: Noemí surname: Rebollo fullname: Rebollo, Noemí organization: Pharmacy Service, University Hospital of Salamanca, Spain – sequence: 3 givenname: José Germán surname: Sánchez-Hernández fullname: Sánchez-Hernández, José Germán organization: Pharmacy Service, University Hospital of Salamanca, Spain – sequence: 4 givenname: Aránzazu surname: Zarzuelo-Castañeda fullname: Zarzuelo-Castañeda, Aránzazu organization: Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain – sequence: 5 givenname: Lourdes surname: Vázquez-López fullname: Vázquez-López, Lourdes organization: Biomedical Research Institute of Salamanca (IBSAL), Spain – sequence: 6 givenname: María José surname: Otero fullname: Otero, María José organization: Pharmacy Service, University Hospital of Salamanca, Spain – sequence: 7 givenname: Jonás Samuel surname: Pérez-Blanco fullname: Pérez-Blanco, Jonás Samuel email: jsperez@usal.es organization: Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34699939$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkE1vFSEUholpY2-rf8CFYelmrgfmk8SNafxKmthFuyYMnFGuDIzAaOqvl-u0Llw0biA5ed6T9zzn5MQHj4S8YLBnwLrXhz0elrTnwFkZdNCIJ2THhl5U0HM4ITsQfKhADP0ZOU_pAADd0MNTclY3nRCiFjuSr8OyOpVt8HT5quKsdPhmPWarEw0TVXQJqcy8-hUc0qxGh5lOIc4PKetpjsqnxSmfqTKrK69z4Qt6tJqmjDPV6ByNqO1i0ef0jJxOyiV8fv9fkNv3724uP1ZXnz98unx7Vemm63IleDM2omVTy9p6HAGUgbqvhTKTYIYrrnBqdW80mHYcBj5iPXYGuFY4TGJg9QWpt72rX9Tdz9JKLtHOKt5JBvLoUB7k0aE8OpSbw5J6taWWGL6vmLKcbTpeoDyGtbBtkVhABgV9eY-u44zm7_YHvwUYNkDHkFLESWqb_3grzqx7vAb_J_pf3d9sISxaf1iMMumiXKOxRX-WJtjH4r8BfJ65UA |
| CitedBy_id | crossref_primary_10_1007_s40265_022_01819_8 crossref_primary_10_1093_jac_dkae160 crossref_primary_10_3389_fphar_2022_1005348 crossref_primary_10_1007_s40262_024_01361_8 crossref_primary_10_1097_FTD_0000000000001319 crossref_primary_10_1007_s13318_024_00916_1 crossref_primary_10_1038_s41598_024_70955_w crossref_primary_10_1111_jcpt_13821 crossref_primary_10_2147_DDDT_S384637 crossref_primary_10_1097_FTD_0000000000001198 crossref_primary_10_1097_FTD_0000000000001196 crossref_primary_10_1128_aac_00077_23 |
| Cites_doi | 10.1111/bcp.13595 10.1016/j.ijantimicag.2012.02.002 10.1128/AAC.01671-10 10.1186/s13054-019-2483-9 10.1093/jac/dkz546 10.1128/AAC.00504-10 10.1128/AAC.02230-17 10.1128/AAC.02465-17 10.1016/j.cmpb.2005.04.005 10.1128/AAC.00157-06 10.2165/00003088-200948030-00001 10.1038/clpt.2010.64 10.1007/s12281-016-0255-4 10.1093/jac/dkx029 10.3324/haematol.2016.152900 10.1097/00007890-197410000-00001 10.1128/AAC.01166-17 10.1016/j.ijantimicag.2010.11.021 10.1128/AAC.01027-09 10.1128/AAC.50.2.658-666.2006 10.1128/AAC.00222-12 10.1128/AAC.03777-14 10.1007/s00228-012-1212-y 10.1038/psp.2013.26 10.1007/s40265-020-01306-y 10.1093/cid/ciu639 10.1007/s10096-011-1288-9 10.1007/s40262-018-0658-1 10.1046/j.1365-2125.2003.01977.x 10.1128/AAC.01034-08 10.1128/AAC.00240-09 10.1093/jac/dkt508 10.1128/AAC.47.9.2788-2795.2003 10.1111/myc.12948 |
| ContentType | Journal Article |
| Copyright | 2021 Copyright © 2021. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2021 – notice: Copyright © 2021. Published by Elsevier B.V. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
| DOI | 10.1016/j.ejps.2021.106049 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-0720 |
| ExternalDocumentID | 10.1016/j.ejps.2021.106049 34699939 10_1016_j_ejps_2021_106049 S0928098721003511 |
| Genre | Journal Article Observational Study |
| GroupedDBID | --- --K --M .~1 0R~ 0SF 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 6I. 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABFRF ABJNI ABLJU ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA GROUPED_DOAJ IHE J1W KOM MO0 N9A O-L O9- OAUVE OGGZJ OK1 OVD OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPCBC SSP SSZ T5K TEORI ~G- 29G 5VS AAQFI AAQXK AATTM AAXKI AAYWO AAYXX ABFNM ABWVN ABXDB ACLOT ACRPL ACVFH ADCNI ADMUD ADNMO ADPDF ADVLN AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN CITATION EFKBS EJD FEDTE FGOYB G-2 HMT HVGLF HZ~ M34 M41 R2- SEW SPT WUQ ~HD BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 ADTOC AGCQF UNPAY |
| ID | FETCH-LOGICAL-c466t-924b4951f5153bb00ad03739adf91d2a2aef5c7dc0d5b882be3b6d02cae8f9813 |
| IEDL.DBID | .~1 |
| ISSN | 0928-0987 1879-0720 |
| IngestDate | Tue Aug 19 18:23:07 EDT 2025 Sat Sep 27 20:58:04 EDT 2025 Thu Apr 03 07:05:09 EDT 2025 Wed Oct 01 02:46:47 EDT 2025 Thu Apr 24 23:03:06 EDT 2025 Fri Feb 23 02:41:19 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Population pharmacokinetics Posaconazole Allogeneic hematopoietic stem cell transplant Model-informed precision dosing |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021. Published by Elsevier B.V. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c466t-924b4951f5153bb00ad03739adf91d2a2aef5c7dc0d5b882be3b6d02cae8f9813 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0928098721003511 |
| PMID | 34699939 |
| PQID | 2587004910 |
| PQPubID | 23479 |
| ParticipantIDs | unpaywall_primary_10_1016_j_ejps_2021_106049 proquest_miscellaneous_2587004910 pubmed_primary_34699939 crossref_citationtrail_10_1016_j_ejps_2021_106049 crossref_primary_10_1016_j_ejps_2021_106049 elsevier_sciencedirect_doi_10_1016_j_ejps_2021_106049 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-01 2022-01-00 2022-Jan-01 20220101 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European journal of pharmaceutical sciences |
| PublicationTitleAlternate | Eur J Pharm Sci |
| PublicationYear | 2022 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Lignell, Löwdin, Cars, Chryssanthou, Sjölin (bib0025) 2011; 55 Ullmann, Cornely, Burchardt, Hachem, Kontoyiannis, Töpelt, Courtney, Wexler, Krishna, Martinho, Corcoran, Raad (bib0041) 2006; 50 Krishna, Ma, Martinho, O'Mara (bib0023) 2012; 56 Du Bois, Du Bois (bib0012) 1989; 5 Courtney, Wexler, Radwanski, Lim, Laughlin (bib0009) 2004; 57 Dolton, Brüggemann, Burger, McLachlan (bib0011) 2014; 58 Soldin, Mattison (bib0036) 2009; 48 Beal, Sheiner, Boeckmann (bib0002) 2009 European Medicines Agency (EMA). Noxafil. Summary of product characteristics Available from Schuetz, Furuya, Schuetz (bib0033) 1995; 275 Lin, Li, Yan, Zhang, Liang, Wang, Xu, Xiang, Xie, Yu, Lan, Peng (bib0026) 2018; 84 Han, Capitano, Bies, Potoski, Husain, Gilbert, Paterson, McCurry, Venkataramanan (bib0018) 2010; 54 Kohl, Müller, Cornely, Abduljalil, Fuhr, Vehreschild, Scheid, Hallek, Rüping (bib0021) 2010; 54 Stott, Hope (bib0037) 2017; 72 Tissot, Agrawal, Pagano, Petrikkos, Groll, Skiada, Lass-Flörl, Calandra, Viscoli, Herbrecht (bib0040) 2017; 102 Wasmann, Smit, Van Donselaar, Van Dongen, Wiezer, Verweij, Burger, Knibbe, Brüggemann (bib0044) 2020; 75 Gubbins, Krishna, Sansone-Parsons, Penzak, Dong, Martinho, Anaissie (bib0017) 2006; 50 Märtson, Veringa, van den Heuvel, Bakker, Touw, van der Werf, Span, Alffenaar (bib0028) 2019; 62 Eiden, Meniane, Peyrière, Eymard-Duvernay, Le Falher, Ceballos, Fegueux, Cociglio, Reynes, Hillaire-Buys (bib0013) 2012; 31 Thompson, Rinaldi, Pennick, Dorsey, Patterson, Lewis (bib0039) 2009; 53 Courtney, Pai, Laughlin, Lim, Batra (bib0008) 2003; 47 Cornely, Duarte, Haider, Chandrasekar, Helfgott, Lopez (bib0007) 2013 (accessed 4.20.21). Perfect, Hachem, Wingard (bib0030) 2014; 59 Sime, Byrne, Parker, Stuart, Butler, Starr, Pandey, Wallis, Lipman, Roberts (bib0035) 2019; 23 Dekkers, Bakker, van der Elst, Sturkenboom, Veringa, Span, Alffenaar (bib0010) 2016; 10 Accessed July 28, 2021. EUCAST, 2021. European Committee on Antimicrobial Susceptibility Testing [WWW Document]. URL Glucksberg, Storb, Fefer, Buckner, Neiman, Clift, Lerner, Thomas (bib0016) 1974 Hoenigl, Raggam, Salzer, Valentin, Valentin, Zollner-Schwetz, Strohmeier, Seeber, Wölfler, Sill, Krause (bib0019) 2012; 39 Krishna, Moton, Lei, Medlock, McLeod (bib0024) 2009; 53 Lindbom, Pihlgren, Jonsson (bib0027) 2005; 79 Chen, Krekels, Verweij, Buil, Knibbe, Brüggemann (bib0006) 2020; 80 R Development Core Team (2012). R: a language and environment for statistical computing. Byon, Smith, Chan, Tortorici, Riley, Dai, Dong, Ruiz-Garcia, Sweeney, Cronenberger (bib0005) 2013; 2 Vehreschild, Müller, Farowski, Vehreschild, Cornely, Fuhr, Kreuzer, Hallek, Kohl (bib0043) 2012; 68 Sheth, Lahiri, Ofotokun (bib0034) 2015 Boonsathorn, Cheng, Kloprogge, Alonso, Lee, Doncheva, Booth, Chiesa, Irwin, Standing (bib0003) 2019; 58 Jang, Colangelo, Gobburu (bib0020) 2010; 88 Suh, H.J., Yoon, H., Yu, K., Cho, J., Park, S., Lee, E., Lee, J., 2018. The Genetic Polymorphism UGT1A4×3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension 62, 1–7. Van Iersel, Rossenu, De Greef, Waskin (bib0042) 2018; 62 Bryant, Slain, Cumpston, Craig (bib0004) 2011; 37 Ashbee, Barnes, Johnson, Richardson, Gorton, Hope (bib0001) 2014; 69 Kraljevic, Khanna, Medinger, Passweg, Masouridi-Levrat, Chalandon, Mueller, Schanz, Vernaz, Van Delden, Neofytos (bib0022) 2020 Petitcollin, Boglione-Kerrien, Tron, Nimubona, Lalanne, Lemaitre, Bellissant, Verdiera (bib0031) 2017; 61 Bryant (10.1016/j.ejps.2021.106049_bib0004) 2011; 37 Boonsathorn (10.1016/j.ejps.2021.106049_bib0003) 2019; 58 Soldin (10.1016/j.ejps.2021.106049_bib0036) 2009; 48 Dekkers (10.1016/j.ejps.2021.106049_bib0010) 2016; 10 Du Bois (10.1016/j.ejps.2021.106049_bib0012) 1989; 5 Sheth (10.1016/j.ejps.2021.106049_bib0034) 2015 Kraljevic (10.1016/j.ejps.2021.106049_bib0022) 2020 Eiden (10.1016/j.ejps.2021.106049_bib0013) 2012; 31 Han (10.1016/j.ejps.2021.106049_bib0018) 2010; 54 Tissot (10.1016/j.ejps.2021.106049_bib0040) 2017; 102 Stott (10.1016/j.ejps.2021.106049_bib0037) 2017; 72 Petitcollin (10.1016/j.ejps.2021.106049_bib0031) 2017; 61 Lignell (10.1016/j.ejps.2021.106049_bib0025) 2011; 55 Thompson (10.1016/j.ejps.2021.106049_bib0039) 2009; 53 Lin (10.1016/j.ejps.2021.106049_bib0026) 2018; 84 Hoenigl (10.1016/j.ejps.2021.106049_bib0019) 2012; 39 Märtson (10.1016/j.ejps.2021.106049_bib0028) 2019; 62 Chen (10.1016/j.ejps.2021.106049_bib0006) 2020; 80 Jang (10.1016/j.ejps.2021.106049_bib0020) 2010; 88 Perfect (10.1016/j.ejps.2021.106049_bib0030) 2014; 59 Gubbins (10.1016/j.ejps.2021.106049_bib0017) 2006; 50 Wasmann (10.1016/j.ejps.2021.106049_bib0044) 2020; 75 Ashbee (10.1016/j.ejps.2021.106049_bib0001) 2014; 69 10.1016/j.ejps.2021.106049_bib0014 10.1016/j.ejps.2021.106049_bib0015 10.1016/j.ejps.2021.106049_bib0038 Ullmann (10.1016/j.ejps.2021.106049_bib0041) 2006; 50 Krishna (10.1016/j.ejps.2021.106049_bib0023) 2012; 56 10.1016/j.ejps.2021.106049_bib0032 Beal (10.1016/j.ejps.2021.106049_bib0002) 2009 Cornely (10.1016/j.ejps.2021.106049_bib0007) 2013 Courtney (10.1016/j.ejps.2021.106049_bib0008) 2003; 47 Dolton (10.1016/j.ejps.2021.106049_bib0011) 2014; 58 Kohl (10.1016/j.ejps.2021.106049_bib0021) 2010; 54 Vehreschild (10.1016/j.ejps.2021.106049_bib0043) 2012; 68 Van Iersel (10.1016/j.ejps.2021.106049_bib0042) 2018; 62 Lindbom (10.1016/j.ejps.2021.106049_bib0027) 2005; 79 Schuetz (10.1016/j.ejps.2021.106049_bib0033) 1995; 275 Krishna (10.1016/j.ejps.2021.106049_bib0024) 2009; 53 Sime (10.1016/j.ejps.2021.106049_bib0035) 2019; 23 Courtney (10.1016/j.ejps.2021.106049_bib0009) 2004; 57 Byon (10.1016/j.ejps.2021.106049_bib0005) 2013; 2 Glucksberg (10.1016/j.ejps.2021.106049_bib0016) 1974 |
| References_xml | – volume: 84 start-page: 1587 year: 2018 end-page: 1597 ident: bib0026 article-title: Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients publication-title: Br. J. Clin. Pharmacol. – volume: 62 start-page: 1 year: 2018 end-page: 11 ident: bib0042 article-title: A population pharmacokinetic model for a solid oral tablet formulation of posaconazole publication-title: Antimicrob. Agents Chemother. – volume: 58 start-page: 53 year: 2019 end-page: 61 ident: bib0003 article-title: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children publication-title: Clin. Pharmacokinet. – volume: 10 start-page: 51 year: 2016 end-page: 61 ident: bib0010 article-title: Therapeutic Drug Monitoring of Posaconazole: an Update publication-title: Curr. Fungal Infect. Rep. – year: 1974 ident: bib0016 article-title: Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors publication-title: Transplantation – volume: 75 start-page: 1006 year: 2020 end-page: 1013 ident: bib0044 article-title: Implications for IV posaconazole dosing in the era of obesity publication-title: J. Antimicrob. Chemother. – volume: 39 start-page: 510 year: 2012 end-page: 513 ident: bib0019 article-title: Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies publication-title: Int. J. Antimicrob. Agents – volume: 61 start-page: 1 year: 2017 end-page: 10 ident: bib0031 article-title: Population pharmacokinetics of posaconazole tablets and monte carlo simulations to determine whether all patients should receive the same dose publication-title: Antimicrob. Agents Chemother. – year: 2020 ident: bib0022 article-title: Swiss Transplant Cohort Study. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients publication-title: Med Mycol – volume: 56 start-page: 4196 year: 2012 end-page: 4201 ident: bib0023 article-title: Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension publication-title: Antimicrob. Agents Chemother. – volume: 48 start-page: 143 year: 2009 end-page: 157 ident: bib0036 article-title: Sex differences in pharmacokinetics and pharmacodynamics publication-title: Clin. Pharmacokinet. – year: 2009 ident: bib0002 article-title: NONMEM 7.1.0 Users Guides (1989-2009) – reference: R Development Core Team (2012). R: a language and environment for statistical computing. – year: 2015 ident: bib0034 article-title: Sex Differences in Metabolism and Pharmacokinetics publication-title: Sex and Gender Differences in Infection and Treatments for Infectious Diseases – volume: 57 start-page: 218 year: 2004 end-page: 222 ident: bib0009 article-title: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults publication-title: Br. J. Clin. Pharmacol. – volume: 54 start-page: 207 year: 2010 end-page: 212 ident: bib0021 article-title: Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation publication-title: Antimicrob. Agents Chemother. – volume: 37 start-page: 266 year: 2011 end-page: 269 ident: bib0004 article-title: A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis publication-title: Int. J. Antimicrob. Agents – volume: 69 start-page: 1162 year: 2014 end-page: 1176 ident: bib0001 article-title: Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology publication-title: J. Antimicrob. Chemother. – volume: 50 start-page: 1993 year: 2006 end-page: 1999 ident: bib0017 article-title: Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients publication-title: Antimicrob. Agents Chemother. – volume: 62 start-page: 698 year: 2019 end-page: 705 ident: bib0028 article-title: Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations publication-title: Mycoses – reference: . Accessed July 28, 2021. – volume: 102 start-page: 433 year: 2017 end-page: 444 ident: bib0040 article-title: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients publication-title: Haematologica – volume: 275 start-page: 1011 year: 1995 end-page: 1018 ident: bib0033 article-title: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms publication-title: J Pharmacol Exp Ther – volume: 5 start-page: 303 year: 1989 end-page: 313 ident: bib0012 article-title: A formula to estimate the approximate surface area if height and weight be known. 1916 publication-title: Nutrition – volume: 50 start-page: 658 year: 2006 end-page: 666 ident: bib0041 article-title: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection publication-title: Antimicrob. Agents Chemother. – volume: 54 start-page: 4424 year: 2010 end-page: 4431 ident: bib0018 article-title: Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients publication-title: Antimicrob. Agents Chemother. – volume: 53 start-page: 958 year: 2009 end-page: 966 ident: bib0024 article-title: Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers publication-title: Antimicrob. Agents Chemother. – volume: 2 start-page: 1 year: 2013 end-page: 8 ident: bib0005 article-title: Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance publication-title: CPT Pharmacometrics Syst. Pharmacol. – volume: 80 start-page: 671 year: 2020 end-page: 695 ident: bib0006 article-title: Pharmacokinetics and Pharmacodynamics of Posaconazole publication-title: Drugs – volume: 47 start-page: 2788 year: 2003 end-page: 2795 ident: bib0008 article-title: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults publication-title: Antimicrob. Agents Chemother. – volume: 58 start-page: 6879 year: 2014 end-page: 6885 ident: bib0011 article-title: Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis publication-title: Antimicrob. Agents Chemother. – volume: 88 start-page: 115 year: 2010 end-page: 119 ident: bib0020 article-title: Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma publication-title: Clin. Pharmacol. Ther. – reference: EUCAST, 2021. European Committee on Antimicrobial Susceptibility Testing [WWW Document]. URL – reference: European Medicines Agency (EMA). Noxafil. Summary of product characteristics Available from: – reference: Suh, H.J., Yoon, H., Yu, K., Cho, J., Park, S., Lee, E., Lee, J., 2018. The Genetic Polymorphism UGT1A4×3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension 62, 1–7. – volume: 53 start-page: 2223 year: 2009 end-page: 2224 ident: bib0039 article-title: Posaconazole therapeutic drug monitoring: a reference laboratory experience publication-title: Antimicrob. Agents Chemother. – volume: 55 start-page: 3099 year: 2011 end-page: 3104 ident: bib0025 article-title: Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration publication-title: Antimicrob. Agents Chemother. – volume: 79 start-page: 241 year: 2005 end-page: 257 ident: bib0027 article-title: PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM publication-title: Comput. Methods Programs Biomed. – volume: 72 start-page: i12 year: 2017 end-page: i18 ident: bib0037 article-title: Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations publication-title: J. Antimicrob. Chemother. – volume: 68 start-page: 987 year: 2012 end-page: 995 ident: bib0043 article-title: Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome publication-title: Eur. J. Clin. Pharmacol. – reference: (accessed 4.20.21). – volume: 23 start-page: 1 year: 2019 end-page: 12 ident: bib0035 article-title: Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients publication-title: Crit. Care – volume: 31 start-page: 161 year: 2012 end-page: 167 ident: bib0013 article-title: Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake publication-title: Eur. J. Clin. Microbiol. Infect. Dis. – volume: 59 start-page: S352 year: 2014 end-page: S355 ident: bib0030 article-title: Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients publication-title: Clin Infect Dis – year: 2013 ident: bib0007 article-title: Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) tablet in patients at risk for invasive fungal infection publication-title: Abstract presented at: 23rd European congress of clinical microbiology and infectious diseases – volume: 5 start-page: 303 year: 1989 ident: 10.1016/j.ejps.2021.106049_bib0012 article-title: A formula to estimate the approximate surface area if height and weight be known. 1916 publication-title: Nutrition – volume: 84 start-page: 1587 year: 2018 ident: 10.1016/j.ejps.2021.106049_bib0026 article-title: Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.13595 – volume: 39 start-page: 510 year: 2012 ident: 10.1016/j.ejps.2021.106049_bib0019 article-title: Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies publication-title: Int. J. Antimicrob. Agents doi: 10.1016/j.ijantimicag.2012.02.002 – ident: 10.1016/j.ejps.2021.106049_bib0015 – volume: 55 start-page: 3099 year: 2011 ident: 10.1016/j.ejps.2021.106049_bib0025 article-title: Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01671-10 – volume: 23 start-page: 1 year: 2019 ident: 10.1016/j.ejps.2021.106049_bib0035 article-title: Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients publication-title: Crit. Care doi: 10.1186/s13054-019-2483-9 – volume: 75 start-page: 1006 year: 2020 ident: 10.1016/j.ejps.2021.106049_bib0044 article-title: Implications for IV posaconazole dosing in the era of obesity publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkz546 – volume: 54 start-page: 4424 year: 2010 ident: 10.1016/j.ejps.2021.106049_bib0018 article-title: Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00504-10 – ident: 10.1016/j.ejps.2021.106049_bib0038 doi: 10.1128/AAC.02230-17 – volume: 62 start-page: 1 year: 2018 ident: 10.1016/j.ejps.2021.106049_bib0042 article-title: A population pharmacokinetic model for a solid oral tablet formulation of posaconazole publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.02465-17 – ident: 10.1016/j.ejps.2021.106049_bib0032 – year: 2020 ident: 10.1016/j.ejps.2021.106049_bib0022 article-title: Swiss Transplant Cohort Study. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients publication-title: Med Mycol – volume: 79 start-page: 241 issue: 3 year: 2005 ident: 10.1016/j.ejps.2021.106049_bib0027 article-title: PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM publication-title: Comput. Methods Programs Biomed. doi: 10.1016/j.cmpb.2005.04.005 – volume: 50 start-page: 1993 year: 2006 ident: 10.1016/j.ejps.2021.106049_bib0017 article-title: Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00157-06 – volume: 48 start-page: 143 year: 2009 ident: 10.1016/j.ejps.2021.106049_bib0036 article-title: Sex differences in pharmacokinetics and pharmacodynamics publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-200948030-00001 – volume: 88 start-page: 115 year: 2010 ident: 10.1016/j.ejps.2021.106049_bib0020 article-title: Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2010.64 – volume: 10 start-page: 51 year: 2016 ident: 10.1016/j.ejps.2021.106049_bib0010 article-title: Therapeutic Drug Monitoring of Posaconazole: an Update publication-title: Curr. Fungal Infect. Rep. doi: 10.1007/s12281-016-0255-4 – volume: 72 start-page: i12 year: 2017 ident: 10.1016/j.ejps.2021.106049_bib0037 article-title: Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkx029 – volume: 102 start-page: 433 year: 2017 ident: 10.1016/j.ejps.2021.106049_bib0040 article-title: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients publication-title: Haematologica doi: 10.3324/haematol.2016.152900 – year: 1974 ident: 10.1016/j.ejps.2021.106049_bib0016 article-title: Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors publication-title: Transplantation doi: 10.1097/00007890-197410000-00001 – volume: 61 start-page: 1 year: 2017 ident: 10.1016/j.ejps.2021.106049_bib0031 article-title: Population pharmacokinetics of posaconazole tablets and monte carlo simulations to determine whether all patients should receive the same dose publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01166-17 – volume: 37 start-page: 266 year: 2011 ident: 10.1016/j.ejps.2021.106049_bib0004 article-title: A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis publication-title: Int. J. Antimicrob. Agents doi: 10.1016/j.ijantimicag.2010.11.021 – volume: 54 start-page: 207 year: 2010 ident: 10.1016/j.ejps.2021.106049_bib0021 article-title: Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01027-09 – ident: 10.1016/j.ejps.2021.106049_bib0014 – volume: 50 start-page: 658 year: 2006 ident: 10.1016/j.ejps.2021.106049_bib0041 article-title: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.50.2.658-666.2006 – volume: 56 start-page: 4196 year: 2012 ident: 10.1016/j.ejps.2021.106049_bib0023 article-title: Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00222-12 – year: 2013 ident: 10.1016/j.ejps.2021.106049_bib0007 article-title: Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) tablet in patients at risk for invasive fungal infection – volume: 58 start-page: 6879 year: 2014 ident: 10.1016/j.ejps.2021.106049_bib0011 article-title: Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.03777-14 – volume: 68 start-page: 987 year: 2012 ident: 10.1016/j.ejps.2021.106049_bib0043 article-title: Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s00228-012-1212-y – volume: 2 start-page: 1 year: 2013 ident: 10.1016/j.ejps.2021.106049_bib0005 article-title: Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance publication-title: CPT Pharmacometrics Syst. Pharmacol. doi: 10.1038/psp.2013.26 – volume: 80 start-page: 671 year: 2020 ident: 10.1016/j.ejps.2021.106049_bib0006 article-title: Pharmacokinetics and Pharmacodynamics of Posaconazole publication-title: Drugs doi: 10.1007/s40265-020-01306-y – year: 2015 ident: 10.1016/j.ejps.2021.106049_bib0034 article-title: Sex Differences in Metabolism and Pharmacokinetics – volume: 59 start-page: S352 issue: Suppl 5 year: 2014 ident: 10.1016/j.ejps.2021.106049_bib0030 article-title: Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients publication-title: Clin Infect Dis doi: 10.1093/cid/ciu639 – volume: 31 start-page: 161 year: 2012 ident: 10.1016/j.ejps.2021.106049_bib0013 article-title: Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake publication-title: Eur. J. Clin. Microbiol. Infect. Dis. doi: 10.1007/s10096-011-1288-9 – volume: 58 start-page: 53 year: 2019 ident: 10.1016/j.ejps.2021.106049_bib0003 article-title: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-018-0658-1 – volume: 57 start-page: 218 year: 2004 ident: 10.1016/j.ejps.2021.106049_bib0009 article-title: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults publication-title: Br. J. Clin. Pharmacol. doi: 10.1046/j.1365-2125.2003.01977.x – volume: 275 start-page: 1011 year: 1995 ident: 10.1016/j.ejps.2021.106049_bib0033 article-title: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms publication-title: J Pharmacol Exp Ther – volume: 53 start-page: 958 year: 2009 ident: 10.1016/j.ejps.2021.106049_bib0024 article-title: Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01034-08 – volume: 53 start-page: 2223 year: 2009 ident: 10.1016/j.ejps.2021.106049_bib0039 article-title: Posaconazole therapeutic drug monitoring: a reference laboratory experience publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00240-09 – volume: 69 start-page: 1162 year: 2014 ident: 10.1016/j.ejps.2021.106049_bib0001 article-title: Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkt508 – year: 2009 ident: 10.1016/j.ejps.2021.106049_bib0002 – volume: 47 start-page: 2788 year: 2003 ident: 10.1016/j.ejps.2021.106049_bib0008 article-title: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.47.9.2788-2795.2003 – volume: 62 start-page: 698 year: 2019 ident: 10.1016/j.ejps.2021.106049_bib0028 article-title: Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations publication-title: Mycoses doi: 10.1111/myc.12948 |
| SSID | ssj0006870 |
| Score | 2.4325132 |
| Snippet | •A popPK model of posaconazole tablets in allogeneic SCT adult recipients is presented.•Gender and serum proteins showed a significant impact on posaconazole... Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT)... |
| SourceID | unpaywall proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 106049 |
| SubjectTerms | Allogeneic hematopoietic stem cell transplant Antifungal Agents - therapeutic use Female Hematopoietic Stem Cell Transplantation Humans Male Model-informed precision dosing Population pharmacokinetics Posaconazole Tablets Triazoles |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS-RAEG7c8SB78LHuriMqJSxediLpPHomRxFFBGUODrin0E9QQxJ2Msj4663KY3zsKnpLOtWhU12d_pqq-oqxX4gQuBEq8aKRNF4kKQiA-3hlXDB0ItKujqq8uBRnk-j8Or5uaXIoF-aF_76Ow7K3JdFqBxwbBOLZL2xZkDOpx5Ynl-OjPzWZHtEsJ3U1PKqe7fnDwG8zZP7_krd2oX9R5le2MstLOb-XWfZs5zlda0oYTWvCQgo4uTucVepQP7yic_zYR62z1RaAwlFjMRtsyebf2MG4YbCeD-DqKSFrOoADGD9xW883WTVeFPyCsn1yh0CVpKFwIKEsptiWy4cis1BRYlYFBIy7Xjc5VDWheoZzCjX9B5DzHw3Z3mggXmkgbwIQ7UZJ2ZrT72xyenJ1fOa1hRs8HQlReXimU3jw4g7BUqhwYUvjh8MwkcYl3AQykNbFemi0b2KFEF_ZUAnjB1rakUtGPPzBenmR2y0G2ijDrRVJEODvxXGpE-UnKjRG4p2Vfca7iUx1y2pOxTWytAtfu01J2SkpO22U3We_F33KhtPjXem4s4-0RSUN2khxWt_tt98ZU4pLljQnc1vMUCgeUVEBXBN99rOxssU4wkggZA-x92Bhdh8Y5PbnxHdYr_o7s7uIpyq11y6kR5J1Hhs priority: 102 providerName: Unpaywall |
| Title | Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients |
| URI | https://dx.doi.org/10.1016/j.ejps.2021.106049 https://www.ncbi.nlm.nih.gov/pubmed/34699939 https://www.proquest.com/docview/2587004910 https://doi.org/10.1016/j.ejps.2021.106049 |
| UnpaywallVersion | publishedVersion |
| Volume | 168 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: ACRLP dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: AIKHN dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-0720 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006870 issn: 1879-0720 databaseCode: AKRWK dateStart: 19930301 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBelfdj2MPa9dG3QYPRl8WLJtmI_hrKSbSwE1kD3ZPQJ6YxtFoeSPexv751sJxsbZezNkk8gdCfpJ-nud4S8AYTAjFBZEKfSBLFEJwAWwpdxfOJErJ33qvw8F7Nl_PEquTog530sDLpVdmt_u6b71bqrGXejOa5Xq_GXMONpCEdmOLT45zCMYI8FuvW9-7l38xCpTxiHwgFKd4EzrY-Xva6RspszqBAh8mn-fXP6E3w-IPc2ZS23N7IoftmQLh6Rhx2SpNO2s4_JgS2fkLNFS0W9HdHLfWTVekTP6GJPUr19SprFLnMXrbs_3wBxojStHJW0rtZQV8ofVWFpgxFWDUWE27dalbTxzOgFKId6Hg-Kr_hgkXalKRJEU3wWoMifUWPY5foZWV68vzyfBV0GhkDHQjQBHM4UnKCYA9QTKZih0oTRJMqkcRkzXHJpXaInRocmUYDVlY2UMCHX0qYuS1n0nByWVWlfEqqNMsxakXEO64RjUmcqzFRkjISSlQPC-qHPdUdPjlkyirz3Q7vOUV05qitv1TUgb3dt6pac407ppNdo_puJ5bB73Nnuda_-HOYejpwsbbUBoSTF7ABg3APyorWLXT-iWAD2jqD1aGco_9DJ4__s5Ctyn2Nghr8cOiGHzfeNPQW41Kihnw9DcjT98Gk2H_pLBygt54vp11u-FRlk |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-69KHbw9hnl31qMPqymPhTsR9LWUnXNgSWQt-EZEmQzthmcRjZX787W3Y3NsrYmy3rQOhOp5-su98BfECEEGiuMi9OpfZiSUEAgY9P2oYzy-PctlGVlws-v4o_XyfXe3DS58JQWKXz_Z1Pb721a5m62ZzW6_X0i5-FqY9HZjy0tNdh92A_TtAnj2D_-Ox8vhgcMk_bmnHU3yMBlzvThXmZm5pYu8MAG7hPlJp_35_-xJ8P4GBb1nL3XRbFL3vS6SN46MAkO-7G-xj2TPkEjpYdG_Vuwla3yVWbCTtiy1ue6t1TaJZD8S5Wuy9fEXRSb1ZZJlldbbCtlD-qwrCGkqwaRiC3l1qXrGnJ0QvUD2upPBhd5KNRmnXOiCOa0c0AIwqNmjIvN8_g6vTT6mTuuSIMXh5z3nh4PlN4iAosAp9I4SKV2o9mUSa1zQIdylAam-Qznfs6UQjXlYkU136YS5PaLA2i5zAqq9K8AJZrpQNjeBaG6CpsIPNM-ZmKtJb4ZuQYgn7qRe4YyqlQRiH6ULQbQeoSpC7RqWsMHweZuuPnuLN30mtU_GZlAjeQO-Xe9-oXuPxo5mRpqi12SlIqEID2PYbDzi6GcUQxR_gdofRkMJR_GOTL_xzkOziYry4vxMXZ4vwV3A8pT6P9V_QaRs23rXmD6KlRb93q-AnUvRlq |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS-RAEG7c8SB78LHuriMqJSxediLpPHomRxFFBGUODrin0E9QQxJ2Msj4663KY3zsKnpLOtWhU12d_pqq-oqxX4gQuBEq8aKRNF4kKQiA-3hlXDB0ItKujqq8uBRnk-j8Or5uaXIoF-aF_76Ow7K3JdFqBxwbBOLZL2xZkDOpx5Ynl-OjPzWZHtEsJ3U1PKqe7fnDwG8zZP7_krd2oX9R5le2MstLOb-XWfZs5zlda0oYTWvCQgo4uTucVepQP7yic_zYR62z1RaAwlFjMRtsyebf2MG4YbCeD-DqKSFrOoADGD9xW883WTVeFPyCsn1yh0CVpKFwIKEsptiWy4cis1BRYlYFBIy7Xjc5VDWheoZzCjX9B5DzHw3Z3mggXmkgbwIQ7UZJ2ZrT72xyenJ1fOa1hRs8HQlReXimU3jw4g7BUqhwYUvjh8MwkcYl3AQykNbFemi0b2KFEF_ZUAnjB1rakUtGPPzBenmR2y0G2ijDrRVJEODvxXGpE-UnKjRG4p2Vfca7iUx1y2pOxTWytAtfu01J2SkpO22U3We_F33KhtPjXem4s4-0RSUN2khxWt_tt98ZU4pLljQnc1vMUCgeUVEBXBN99rOxssU4wkggZA-x92Bhdh8Y5PbnxHdYr_o7s7uIpyq11y6kR5J1Hhs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Population+pharmacokinetics+of+a+posaconazole+tablet+formulation+in+transplant+adult+allogeneic+stem+cell+recipients&rft.jtitle=European+journal+of+pharmaceutical+sciences&rft.au=Pe%C3%B1a-Lorenzo%2C+Diego&rft.au=Rebollo%2C+Noem%C3%AD&rft.au=S%C3%A1nchez-Hern%C3%A1ndez%2C+Jos%C3%A9+Germ%C3%A1n&rft.au=Zarzuelo-Casta%C3%B1eda%2C+Ar%C3%A1nzazu&rft.date=2022-01-01&rft.pub=Elsevier+B.V&rft.issn=0928-0987&rft.eissn=1879-0720&rft.volume=168&rft_id=info:doi/10.1016%2Fj.ejps.2021.106049&rft.externalDocID=S0928098721003511 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0928-0987&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0928-0987&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0928-0987&client=summon |